EE401 Cost-Effectiveness of OMNI® Surgical System Versus iStent Inject® for the Treatment of Primary Open-Angle Glaucoma in the United States

OMNI® Surgical System has demonstrated in clinical trials a reduction in intraocular pressure (IOP) both as a standalone procedure or combined with cataract surgery in eyes with mild to moderate primary open-angle glaucoma (POAG). Clinical data on efficacy and safety of OMNI Surgical System are published in the literature; however, the cost-effectiveness of OMNI Surgical System has not been studied. The objective of this analysis is to estimate the cost-effectiveness of the OMNI Surgical System versus iStent Inject for the treatment of primary open-angle glaucoma (POAG) in combination with cataract surgery.